Pyridostigmine Bromide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg, 90 mg,180 mg
Reference Brands: Mestinon (USA)
Category:
Neurology
Pyridostigmine Bromide is available in Tablets
and strengths such as 60 mg, 90 mg,180 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pyridostigmine Bromide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pyridostigmine Bromide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pyridostigmine bromide, marketed under the brand name Mestinon, is an orally active cholinesterase inhibitor used to treat muscle weakness in patients with myasthenia gravis and certain forms of congenital myasthenic syndrome. By preventing the breakdown of acetylcholine at neuromuscular junctions, pyridostigmine improves nerve-to-muscle signaling and enhances muscle strength and control.
In addition to its use in neuromuscular disorders, pyridostigmine is administered alongside atropine to reverse the effects of non-depolarizing neuromuscular blocking agents and is also used to manage underactive bladder. Pyridostigmine bromide has been FDA-approved for military use as a pre-exposure agent to nerve toxins such as Soman, improving survival during combat situations. Its effects typically begin within 45 minutes of administration and last up to four hours, making it suitable for both acute and ongoing symptom management.
Pyridostigmine is available in oral tablet and extended-release formulations, and in some cases, injectable forms are used under clinical supervision. Its well-established mechanism as a cholinesterase inhibitor, combined with a history of both therapeutic and specialized applications, makes pyridostigmine an essential agent in neurology, urology, and certain defense-related medical protocols.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing